

DAFTAR PUSTAKA

1. Global initiative for chronic obstructive lung diseases (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary diseases. National institutes of health national heart , lung and Blood institute, update 2016
2. Chapman KR, Manninodm, Soriano JB, Vermeire PA, Buist AS, Thun MJ ,et al. Epedimiology and cost of COPD . *EurRespir J* 2006; 27 : 188-207
3. Sethi S. bacteria infection and chronic obstructive pulmonary diseases in 2000: a state of the art review. *Clinical Microbiology Riview* 2001; 14: 336-63
4. Sethi S and Murphy TF . Infection in Pathogenesis and course of Chronic Obstructive Pulmonary Disease. *The New England Journal of Medicine* 2008; 359: 2355-65
5. Tang H, Fang Z, Saborio G B, Xiu Q. Efficacy and safety of OM-85 on Patient with Chronic bronchitis and/or chronic obstructive pulmonary diseases. *Lung DOI* 2015;10: 9737-43
6. Massag S.D and Johnston S.L. Infection. In: Barnes PJ, Drazen JM, Rennard SI and Thomson ed. *Asthma and COPD*. USA: Elsevier; 2009.p.456-78
7. Sethi S and Murphy T.F. Bacterial infection in chronic obstructive pulmonary disease in 2001;14;p.336-63
8. Miravitles M, Marin A, Monso E, Vila S, Roza CDI, Herves R et all. Color of sputum is a marker for bacteria colonization in chronic obstructive pulmonary disease. *Respiratory Research* 2010;11-58
9. Schembri S, Morant S, Winter JH, Macdonald T M. Influenza but not Pneumococcal vaccination protects against all-cause mortality in patient with COPD. *Thorax* 2009;64:567-72
10. Wilkinson T.M.A, Patel I.S, Wilks M, Donaldson GC and Wedzicha JA. Airway bacterial load and FEV1 decline in patient with chronic obstructive pulmonary disease. *Am Respire Crit Care Med*. 2003;167:1090-5
11. Emmerich B, Emslander HP, Pachman K, Hallek M, Milatovic D, Busch R. Local immunity in patient with chronic bronchitis and the effect of a bacterial extrac, Broncho-Vaxom, on T Lymphocytes, macrophages, Gamma-interferon and secetary Immunoglobulin A in Bronchoalveolar lavage fluid and other Variabels. *Respiration* 1990;57:90-9
12. PerhimpunanDokterParu Indonesia. *PenyakitParuObstruktifKronik (PPOK), Diagnosis danPaenatalaksanaan*. PDPI. Jakarta. 2016
13. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. *The Lancet* 1997; 349: 1498-504

14. Hao-yan W, Jian-kun L, Hui-xue H, Xin-zhi W. Relationship among bacterial colonization, airway inflammation and bronchodilator response in patient with stable COPD. *Chin Med J* 2006;119:684-7
15. MacNee W. Pathology and Pathogenesis. In: Currie G.P ed. *ABC of COPD*. UK:Wiley-Blackwell;2011.p.6-11
16. Roinsin R.R and MacNee W. Pathophysiology of chronic obstructive pulmonary disease. *Eur Respir Mon* 2006;38:177-200
17. Sohy C, Pilette C, Niederman MS, et al. Acute exacerbation of chronic pulmonary disease and antibiotic: what studies are still needed?. *Eur Respir J* 2002;19:966-75
18. MacNee W. ABC of chronic obstructive pulmonary disease. Pathology, pathogenesis, and pathophysiology. *BMJ* 2006;332:1202-4
19. Casio MG, Majo J. Inflammation of the Airways and Lung Parenchyma in COPD. *Chest* 2002;121:160-5
20. Donohue JF, Sheth K. *Asthma and COPD Management Strategies for the Primary Care Provider*. USA: AKH. 2006
21. Mahler DA. Mechanism and measurement of dyspnea in COPD. *Proc Am Thorac Soc* 2006;3:p.234-38
22. O'Donnell D.E, Banzett R.B, Kohlman V.C, Casaburi R, Davenport P.W, Gandevia S.C et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease. *Proc Am Thorax Soc* 2007;4:p.145-68
23. Mahler DA, Criner G.J. Assessment tools for COPD : Do newer metrics allow for disease modification. *Proc Am Thoracic Medicine* 2007;4:p.507-11
24. Bestal J.C, Paul E.A, Garrod R, Garnham R, Jones D.W, Wedzicha. Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with COPD. *Thorax* 1999;54:581-86
25. Sethi S, Maloney J, Grove L and Berenson C.S. Airway inflammation and bronchial colonization in chronic obstructive pulmonary disease. *Am Respir Crit Care Med* 2006;99:1-8
26. Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease. 2011;52:290-5
27. Banerjee D, Khair O.A and Honeybourne. D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. *Eur Respiratory Journal* 2004;23:685-91
28. Sethi S and Murphy T.F. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state – of – the – art review. *Clinical Microbiology review* 2001;14:336-63
29. Soler N, Ewing S, Torres A, Filella X, Gonzales J and Zaubert A. Airway inflammation and bronchial microbial patterns in patient with stable chronic obstructive pulmonary disease. *Eur Respir J* 1999;14:1015-22

30. Rosel A, Monso E, Soler N, Torres F, Angrill J, Riise G et al. Microbiologic determinant of exacerbation in chronic obstructive pulmonary disease. *Arch Intern Med* 2006;165:891-7
31. Patel I.S, Seemungal T.A.R, Wilk M, Owen SJL, Donaldson GC and Wedzicha JA. Relationship between bacterial colonization and the *frequency, character and severity of COPD exacerbation*. *Thorax*. 2002;57:759-64
32. Sethi S. Bacteria infection in chronic obstructive pulmonary disease. In: *Chronic obstructive pulmonary disease*. Ed Voelkel NF and MacNee W.BC Decker Inc.India. 2008; 187-203
33. Nigou J, Zelle-Reiser C, Gilleron M, Turnhner M, Puzo G. MannosylatedLipoarabinomannans inhibit IL-12 production by Human Dendritic Cells : Evidence for negative signal delivered Throuth of Mannose reseptor. *J Immunol* 2001;166: 7477-85
34. Soler M, Mutterlein R, Cozma G. Double Blind Study of OM-85 in Patient with Chronic Bronchitis or Mild Chronic Obstructive Pulmonary Diseases. *Respiration* 2007;74: 26-32
35. Arslan RS, Ozdemir L, Yilmaz B, Unal O, Akkaya E. CRP association betwen C Reactive Protein And Chrinic ObsriuctivePulmonary Disease. *Jour Clin Anal Med* 2013;4:120-3.
36. Aksu F, Capan N, Aksu K, OfluogleR, Canbakan S, Yavuz , et al. C Reactive protein levels are raised in stable Chronic obstructive pulmonary disease patient independent of smoking behavior and biomass exposure. *Jour Thorac Dis* 2013;5(4):414-21.
37. DeMeo DL and Weiss ST. eepidemiology. In Barnes PJ, Drazen JM, rennard SI anf Thomson ed. *Asthma and COPD*. USA :Elsivier;2009.p.9-22.
38. Sitompul P.A. hubungan kolonisasi bakteri jalan nafas bawah dengan inflamasi, fungsi paru dan klinis pada penyakit paru obstruktif kronik stabil. Tesis Bagian Pulmonologi dan kedokteran Respirasi FK UI.Jakarta.2008
39. Senior RM, Atkinson JJ, Chronic Obstructive pulmonary diseases: Epidemiology, Pathophysiology, and Pathogenesis. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, eds. *Fisman's Pulmonary Desiases and disorders*. Fourth edition ed.New York: Mc Graw Hill Medical 2008: 707-27.
40. Chung KF, Adock IM. Multifaceted mechanism in COPD: iflamation,immunity, and tissue repair and destruction. *Eur Respir J* 2008;31:1334-56
41. Ferrari R, Tanni SE, Caram LM, Correa C, Coerea CR, Godoy I, Three-year foloow up of interleukin and C=Reactive Proteinin Chronic obstructive pulmonary disesase. *Bio Med Central* 2011;14:1-7..
42. Braido F, Tarantini F, Ghiglione V, Melioli G, Canonica GW .Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections *International Journal of COPD* 2007;2(3) 335–45.

43. Zagólski O, Strępek P, Kasprówicz A, Białeckaa A. Effectiveness of Polyvalent Bacterial Lysate and Autovaccines Against Upper Respiratory Tract Bacterial Colonization by Potential Pathogens: A Randomized Study. *Med Sci Monit*, 2015; 21: 2997-3002.

